iRadimed Corporation

Stage 4 · Declining · week 9

As of Oct 22, 2026, iRadimed is in Stage 4, the downtrend phase, now in week 9 (since Aug 24, 2026). It closed at $87.64, 16.2% below its 52-week high and below its 200-day average, which is falling.

$87.64

-0.19% today

$1.1B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is IRMD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S2 37w

S2 44w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 4w → S3 8w → S4 7w → S1 7w → S2 4w → S4 15w → S1 1w → S2 37w → S3 9w → S4 1w → S3 1w → S2 44w → S3 11w → S4 2w → S2 6w → S1 1w → S4 9w current

Total tracked: 164 weeks across 17 stage runs.

IRMD among Medical Devices34th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…34	IRMDiRadimed Corporation	Stage 4 · wk 9	68	+1.5%

vs 52W High

-16.2%

$75.38 lo$104.63 hi

16.2% below 52W high, ongoing decline

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 9

1w13w26w

Week 9, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-5.5%

200 DMA: $92.72 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.81x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↗ ⇈

Short-term trend rising gently, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+1.5%

-7.0%

-0.9%

YTD

-7.6%

+17.7%

Scan Membership

Breakout Watch

Latest: 2025-06-03

10 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 9 · Vol 0.81x

2026-10-21S4

Wk 9 · Vol 0.45x

2026-10-20S4

Wk 9 · Vol 0.70x

2026-10-19S4

Wk 8 · Vol 0.67x

2026-10-16S4

Wk 8 · Vol 0.66x

2026-10-15S4

Wk 8 · Vol 0.67x

2026-10-14S4

Wk 8 · Vol 0.59x

2026-10-13S4

Wk 8 · Vol 0.75x

2026-10-12S4

Wk 7 · Vol 0.86x

2026-10-09S4

Wk 7 · Vol 0.53x

2026-10-08S4

Wk 7 · Vol 0.70x

2026-10-07S4

Wk 7 · Vol 1.53x

Moving averages & range

50 DMA

$86.11

200 DMA

$92.72

52W High

$104.63

52W Low

$75.38

5D Low

$87.64

Resistance levels (recent highs)

20d High

$89.83

60d High

$94.99

120d High

$102.07

250d High

$104.63

Next resistance

+2.5%

to 20d High

P/E (TTM)

49.0

Forward 35.7

Earnings Growth (YoY)

-9.3%

Revenue +0.3%

ROE

+23.5%

Profit margin +26.7%

Dividend Yield

0.91%

P/B 11.0

iRadimed: quick answers

What stage is iRadimed in?

As of Oct 22, 2026, iRadimed (IRMD) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 24, 2026 and is in week 9. What the four stages mean

Is iRadimed in an uptrend?

No. iRadimed is in a Stage 4 downtrend. It trades 5.5% below its 200-day average, which is falling.

How far is iRadimed from its 52-week high?

iRadimed closed at $87.64 on Oct 22, 2026, 16.2% below its 52-week high of $104.63. Its 52-week low is $75.38.

How has iRadimed performed over the past year?

As of Oct 22, 2026, iRadimed is up 17.7% over the past year and down 7.6% so far in 2026.

Which sector and industry is iRadimed in?

iRadimed is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.